Menu
09:00 – 09:30: Doors open and welcome coffee
09:30 – 09:45: Welcome by HST Group – BioWin – MEDVIA
09:45 – 10:15: Keynote “What can the study of R&D productivity tell us about hopes for AI?”, Jack Scannell, Etheros Pharmaceuticals Corp.
10:15 – 10:45: Keynote “Promises and challenges of AI in drug discovery”, Yves Moreau, University of Leuven
10:45 – 11:15: Coffee break and networking
11:15 – 11:45: Case studies session:
11:45 – 12:15: Keynote “New strategic research program on the advancement of the discovery and development of therapeutics”, imec & VIB
12:15 – 13:30: Lunch and networking
13:30 – 13:40: Setting the scene, Benoit Van den Eynde, UCL
13:40 – 13:55: Kathleen Marchal and Thomas Demeester, UGent-imec
13:55 – 14:10: “Nemo project: optimising bioprocess development with informed design of experiment”, Julien de Crom, UCB
14:10 – 14:25: “CombinAge: The power of graph ML for discovering novel targets and drug combinations”, Gabriel Risa, Rejuvenate Biomed
14:25 – 14:40: “AI powered, patient-centric solutions”, Maxim Le Compte, Sightera Biosciences (spin-off Uantwerp and UZA)
13:30 – 13:40: Setting the scene, Isabelle Salmon, Erasme Hospital, ULB
13:40 – 13:55: “The role of digital pathology and biomarker profiling through machine learning”, Frederik Deman, ZAS
13:55 – 14:10: “Gloria project: European platform storing digital DNA”, Aloys du Bois d’Aische, Eonix
14:10 – 14:25: “Detecting rheumatic diseases up to 10 years before diagnosis is made”, Nicolaas Fosselle, Rheumafinder
14:25 – 14:40: “Data and digitalization in the context of prevention”, Nathalie Lambrechts, VITO
14:40 – 15:10: Coffee break and networking
15:10 – 15:15: Welcome afternoon program, HST
15:15 – 15:45: “The use of health data for research purposes in Belgium: framework, challenges and operational implementation”
Moderated by Liesbet Peeters, UHasselt
15:45 – 16:15: Keynote “Artificial Intelligence: Hindsight, Insight, Foresight”, Mieke De Ketelaere, Vlerick Business School
16:15 – 17:15: Closing roundtable: Unlocking AI’s Potential in Healthcare and Drug Discovery: Is Belgium Falling Behind?
Artificial Intelligence is revolutionizing healthcare and drug discovery, but is Belgium seizing this incredible opportunity? How does Europe stack up against global powerhouses in this field, and which regions should we be watching—and collaborating with?
Join us as we explore why some Belgian companies are relocating outside of Belgium, and even Europe, to fully capitalize on these emerging trends. Are we missing critical opportunities at home? What can be done to strengthen our position, and what challenges do we face in becoming a global leader?
Let’s discuss strategies, opportunities, and solutions for Belgium to better harness AI’s transformative power in healthcare.
Moderated by Bart Vannieuwenhuyse.
17:15 – 17:20: Conclusion, invite to the reception
Cookies